drugset / Trial / NCT01865279

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec

NCT01865279

Phase 1 Completed 64 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of insulin degludec (insulin 454), an explorative formulation, not similar to the proposed commerical formulation.

Timeline

Start
2005-12
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin degludec Protein / enzyme biologic
Comparator isophane human insulin Protein / enzyme biologic 0.4 iu/kg
Comparator isophane human insulin Protein / enzyme biologic 0.6 iu/kg